Octreotide + Placebo + Everolimus
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Tumor
Conditions
Carcinoid Tumor, Malignant Carcinoid Syndrome
Trial Timeline
Dec 1, 2006 → Jun 1, 2013
NCT ID
NCT00412061About Octreotide + Placebo + Everolimus
Octreotide + Placebo + Everolimus is a phase 3 stage product being developed by Novartis for Carcinoid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT00412061. Target conditions include Carcinoid Tumor, Malignant Carcinoid Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00412061 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoid Tumor